Heme oxygenase-1
(HO-1) promotes heme catabolism exercising cytoprotective
roles in normal and cancer cells. Herein, we report the design, synthesis,
molecular modeling, and biological evaluation of novel HO-1 inhibitors.
Specifically, an amide linker in the central spacer and an imidazole
were fixed, and the hydrophobic moiety required by the pharmacophore
was largely modified. In many tumors, overexpression of HO-1 correlates
with poor prognosis and chemoresistance, suggesting the inhibition
of HO-1 as a possible antitumor strategy. Accordingly, compounds
7i
and
7l
–
p
emerged for their
potency against HO-1 and were investigated for their anticancer activity
against prostate (DU145), lung (A549), and glioblastoma (U87MG, A172)
cancer cells. The selected compounds showed the best activity toward
U87MG cells. Compound
7l
was further investigated for
its in-cell enzymatic HO-1 activity, expression levels, and effects
on cell invasion and vascular endothelial growth factor (VEGF) extracellular
release. The obtained data suggest that
7l
can reduce
cell invasivity acting through modulation of HO-1 expression.